Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.97 | N/A | -11.75% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.97 | N/A | -11.75% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management conveyed a cautious outlook, acknowledging the difficulties faced while remaining focused on long-term goals.
Management highlighted ongoing challenges in the current market environment.
They emphasized their commitment to advancing their pipeline despite recent setbacks.
Kodiak Sciences reported a larger-than-expected loss per share, which reflects ongoing challenges in their operations. Despite this, the stock rose by 4.48%, likely driven by investor optimism about future developments in their pipeline. The lack of revenue data and guidance may leave some investors uncertain about the company's immediate prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BUILDERS FIRSTSOURCE
Feb 26, 2021